Irafamdastat not checked
Celgene · CC-97489 · BMS-986368
FollowEvery change as it happens, and a Monday email
Trials
4 active
9 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Multiple Sclerosis Spasticity, Agitation, Alzheimer Disease
- Main trialPhase 2
- “The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity”In the company’s words, NCT06782490 on ClinicalTrials.gov
- Other names
- CC-97489 · BMS-986368
Other drugs for Multiple Sclerosis Spasticity
- ArbaclofenRVL Pharmaceuticals, Inc. · Phase 3
- MELPIDAElpida Therapeutics SPC · Phase 1/2
- AbobotulinumtoxinAIpsen · Phase 1/2
- CorabotaseIpsen · Phase 1/2
- BFB-101BlackfinBio Ltd · Phase 1/2
Coming up4
- 19 DecPhase 1 trial completes · ClinicalTrials.gov
- 23 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 26 May 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Nov 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 26 May 2027 | A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | |
| Phase 2Recruiting | 26 Nov 2027 | Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | |
| Phase 1Recruiting | 19 Dec 2026 | A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants | |
| Phase 1Not yet recruiting | 23 Feb 2027 | A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants | |
| Phase 1Terminated | 11 Jul 2022 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants | |
| Phase 1Completed | 29 Jan 2024 | Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants | |
| Phase 1Completed | 3 Apr 2024 | A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants | |
| Phase 1Completed | 25 May 2024 | A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants | |
| Phase 1Completed | 28 Oct 2024 | A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026